ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Cefiderocol for the Treatment of Metallo-β-Lactamases Producing Gram-Negative Bacilli: Lights and Shadows From the Literature.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- An integrated phenotypic and genomic approach to characterize MBL-producing Enterobacterales strains circulating in a Sicilian transplant center.Microbiology spectrum · 2026Article
- Avibactam-based combinations for the treatment of multidrug resistant Gram-negative bacilli infections.Le infezioni in medicina · 2026Review
- The burden of infections caused by Metallo-Beta-Lactamase-Producing Enterobacterales in Italy: epidemiology, outcomes, and management.Le infezioni in medicina · 2025Review
- Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.Current issues in molecular biology · 2024Review
- Review
- Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.Infectious diseases and therapy · 2024Article
- Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales.Infectious diseases and therapy · 2023Review
- Real-world experience with cefiderocol therapy forAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement.Journal of anesthesia, analgesia and critical care · 2022Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
35136982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.